Given the growing prevalence of type 2 diabetes (T2D) and its contribution to cardiovascular disease, cardiovascular outcomes trials should aim to be more representative of the average patient with T2D.
Anne Peters, MD
Advertisement
Articles by Anne Peters, MD
Formularies of the future should use evidence-produced CER to better target, not limit, diabetes care.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Real-World Data Show MASH Progresses Faster Than Trials Suggest
2
Adam Kittai, MD, on Sequencing, Cost, and the Road to CLL Cure
3
SYNC-T: Immunotherapy Platform Brings 4-Part Attack in Prostate Cancer, With More Trials Planned
4
Kazia Therapeutics Discusses Shift for Paxalisib Into Triple-Negative Breast Cancer
5